Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 3/20 | 0.31 |
| ▸ | GCKR | Q14397 | 3/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5245169 | 0.80 | PDPK1 (0.36) | PDPK1MEN1KMT2A | |
| SCHEMBL7671297 | 0.75 | MCHR1 (0.33) | GCKGCKRMAP3K5 | |
| SCHEMBL23910865 | 0.74 | ACACB (0.34) | PDPK1MEN1KMT2A | |
| SCHEMBL23910947 | 0.73 | LMNA (0.32) | — | |
| SCHEMBL1850156 | 0.72 | USP7 (0.40) | USP7 | |
| SCHEMBL7123618 | 0.70 | MCHR1 (0.32) | GCKGCKR | |
| SCHEMBL23911563 | 0.70 | MAPKAPK2 (0.34) | USP7 | |
| SCHEMBL2209771 | 0.70 | KIT (0.35) | USP7MEN1KMT2A | |
| SCHEMBL29808576 | 0.70 | KIT (0.35) | USP7MEN1KMT2A | |
| SCHEMBL28375772 | 0.69 | PSMB8 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | PDPK1 2364/4885USP7 1/4885GCK 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.